Aclaris Therapeutics, Inc.

ACRSNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
4.36 USD
↗ 0.00 (0.00%)AT CLOSE (11:59 AM EDT)
4.32
↘ 0.04 (0.92%)
POST MARKET (AS OF 06:30 PM EDT)
Post Market
AS OF 06:30 PM EDT
4.32
↘ 0.04 (0.92%)
🔴Market: CLOSED
Open?$4.69
High?$4.70
Low?$4.33
Prev. Close?$4.36
Volume?929.0K
Avg. Volume?1.2M
VWAP?$4.42
Rel. Volume?0.74x
Bid / Ask
Bid?$4.30 × 300
Ask?$4.88 × 100
Spread?$0.58
Midpoint?$4.59
Valuation & Ratios
Market Cap?608.9M
Shares Out?139.7M
Float?98.4M
Float %?81.6%
P/E Ratio?N/A
P/B Ratio?4.24
EPS?-$0.50
Dividend?0.00%
Ex-Dividend?N/A

ACRS is currently priced at $4.37. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Furthermore, ACRS is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Themes
Biotech - Drug Development›Immunology & Autoimmune
Employees
73
Market Cap
608.9M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.aclaristx.com
Listed
2015-10-07
Address
701 LEE ROAD
WAYNE, PA 19087
Phone: 484-324-7933
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
1
Momentum?
80
Short Sent.?
45
Piotroski F-Score?2/9Weak
Altman Z-Score?-1.12Distress
Confidence?51%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?7.47%Elevated
Short Interest?7.3M
Days to Cover?5.6
Free Float98.4M
Avg Daily Volume1.3M
Settlement Date2026-05-15
Financial Health
Current Ratio?4.03Strong
Quick Ratio?4.03Strong
Cash Ratio?1.05Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
42
4.24FAIR▾
P/S?
Peers
100
S&P
3
72.78HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-7.4CHEAP▾
EV/Sales?
Peers
100
S&P
3
69.35HIGH▾
Returns & Efficiency
ROE?
S&P
3
-48.5%WEAK▾
ROA?
S&P
3
-35.1%WEAK▾
Cash Flow & Enterprise
FCF?$-51986000
Enterprise Value?$580.3M
Fundamentals ratios updated end of day
MarketsMoversWatchlist